Pacira BioSciences
PCRX
267 hedge funds and large institutions have $1.89B invested in Pacira BioSciences in 2023 Q1 according to their latest regulatory filings, with 42 funds opening new positions, 105 increasing their positions, 81 reducing their positions, and 45 closing their positions.
30% more repeat investments, than reductions
Existing positions increased: 105 | Existing positions reduced: 81
17% more call options, than puts
Call options by funds: $7.27M | Put options by funds: $6.19M
3% more capital invested
Capital invested by funds: $1.84B → $1.89B (+$55.7M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7% less first-time investments, than exits
New positions opened: 42 | Existing positions closed: 45
2% less funds holding
Funds holding: 273 → 267 (-6)
4.7% less ownership
Funds ownership: 105.57% → 100.87% (-4.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$21.6M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$19.1M |
| 3 |
Millennium Management
New York
|
+$17.3M |
| 4 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$12.2M |
| 5 |
BlackRock
New York
|
+$10.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$73.1M |
| 2 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$47.7M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$31.9M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$11.3M |
| 5 |
DM
Deerfield Management
New York
|
-$11.3M |
PCRX Hedge Fund Activity: Q1 2023 in Review
267 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q1 2023, worth a combined $1.89B — up 3% from $1.84B a quarter earlier.
Sellers outnumbered buyers: 45 funds closed out of PCRX and 42 opened new positions — a net loss of 3 holders — while 81 trimmed existing stakes and 105 added.
The largest buyer was Frontier Capital Management, adding an estimated $21.6M. The largest seller was Armistice Capital, exiting entirely with an estimated $73.1M sold.
- 267 institutional investors held Pacira BioSciences (PCRX) as of Q1 2023, down from 273 in Q4 2022.
- Funds reported $1.89B of Pacira BioSciences stock for Q1 2023, up 3% quarter-over-quarter.
- 42 funds opened new Pacira BioSciences positions in Q1 2023 and 45 closed out, a net change of -3 holders.
- The largest Pacira BioSciences buyer in Q1 2023 was Frontier Capital Management, an estimated $21.6M added.
- The largest Pacira BioSciences seller in Q1 2023 was Armistice Capital, an estimated $73.1M sold.
Based on aggregated 13F filings for Q1 2023.